Waldencast Acquisition Corp. ( (WALD) ) has released its Q3 earnings. Here is a breakdown of the information Waldencast Acquisition Corp. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Waldencast Acquisition Corp. is a global multi-brand beauty and wellness platform that focuses on developing, acquiring, and scaling purpose-driven brands in the beauty industry. The company operates through its two main brands, Obagi Medical and Milk Makeup.
In its latest earnings report, Waldencast highlighted a mixed performance across its brands for Q2 and Q3 2025. Obagi Medical showed strong revenue growth, particularly in e-commerce and international markets, while Milk Makeup experienced growth in the U.S. but faced challenges internationally.
Key financial metrics revealed a 5.6% year-over-year increase in net revenue for Q2 2025, reaching $66.8 million, with an adjusted EBITDA margin of 5.0%. Obagi Medical’s revenue grew by 10.1% in Q3 2025, while Milk Makeup saw a decline due to softer international market performance. Strategic initiatives included the acquisition of Novaestiq and the sale of the Obagi Japan trademark, strengthening the company’s balance sheet.
Looking ahead, Waldencast’s management remains optimistic about long-term growth, with a focus on strategic investments and innovation. The company expects net revenue for the full year to align with 2024 levels, with an adjusted EBITDA margin in the high single digits, reflecting a moderated outlook for Milk Makeup.
Overall, Waldencast continues to advance its strategic priorities, aiming to maximize shareholder value through ongoing evaluations and potential strategic alternatives.